Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESETTLE: Young adults with early-onset obesity treated with semaglutide
2024-518086-99-00Phase 4Completed
- Sponsor
- University of Copenhagen
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of semaglutide in obesity (4 arms), sponsored by University of Copenhagen. Primary endpoint: Change in BMI from baseline to post-treatment. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2024-518086-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518086-99-00.